Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00416455
Other study ID # NCI-2009-00600
Secondary ID NCI-2009-00600CD
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 2007
Est. completion date July 16, 2016

Study information

Verified date November 2018
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I/II trial is studying how well fludeoxyglucose F 18 PET scan, CT scan, and ferumoxtran-10 MRI scan finds lymph node metastasis before undergoing chemotherapy and radiation therapy in patients with locally advanced cervical cancer or high-risk endometrial cancer. Diagnostic procedures, such as a fludeoxyglucose F 18 positron emission tomography (PET) scan, computed tomography (CT) scan, and ferumoxtran-10 magnetic resonance imaging (MRI) scan, may help find lymph node metastasis in patients with cervical cancer or endometrial cancer.


Description:

PRIMARY OBJECTIVES:

I. Determine the diagnostic sensitivity and specificity of preoperative fludeoxyglucose F 18 positron emission tomography (FDG-PET)/CT scanning and ferumoxtran-10 MRI scanning in identifying metastases to abdominal (common iliac, para-aortic, and paracaval) lymph nodes in patients with locoregionally advanced cervical carcinoma.

II. Determine the diagnostic sensitivity and specificity of preoperative FDG-PET/CT scanning and ferumoxtran-10 MRI scanning in identifying metastases to retroperitoneal abdominal lymph nodes in patients with high-risk endometrial cancer.

SECONDARY OBJECTIVES:

I. Determine the diagnostic sensitivity and specificity of preoperative FDG-PET/CT scanning and ferumoxtran-10 MRI scanning in identifying metastases to pelvic lymph nodes and pelvic and abdominal lymph nodes combined in patients with locoregionally advanced cervical carcinoma or high-risk endometrial cancer.

II. Compare the additive diagnostic value of CT fusion (PET/CT scan) vs PET scanning alone in identifying metastases to pelvic, abdominal, and combined (all regions) lymph nodes in these patients.

III. Compare the diagnostic sensitivity and specificity of PET/CT scanning vs ferumoxtran-10 MRI scanning in identifying metastases to pelvic, abdominal, and combined lymph nodes in these patients.

IV. Compare the diagnostic sensitivity and specificity of ferumoxtran-10 MRI vs MRI alone, in terms of size criteria in the abdomen and pelvis, in these patients.

V. Determine the percentage of patients with locoregionally advanced cervical cancer or high-risk endometrial cancer who have biopsy-proven disease outside the abdominal or pelvic lymph nodes detected by PET/CT scanning.

VI. Determine the accuracy of MRI in determining the depth of myometrial invasion and involvement of cervix in patients with high-risk endometrial cancer.

VII. Determine the complications associated with extraperitoneal or laparoscopic abdominal and pelvic lymphadenectomy in patients with locoregionally advanced cervical cancer.

VIII. Determine the cause(s) of delay in the initiation of radiotherapy or interruption in radiotherapy in patients with locoregionally advanced cervical cancer.

IX. Collect data on the adverse effects of ferumoxtran-10 in patients with locoregionally advanced cervical carcinoma or high-risk endometrial cancer.

X. Compare the size of lymph nodes in pre- and post-ferumoxtran-10 MRI's in a subset of forty patients.

OUTLINE: This is a multicenter study.

Patients receive fludeoxyglucose F 18 (FDG) IV followed 60 minutes later by positron emission tomography (PET)/CT scanning on day 1. Patients also receive ferumoxtran-10 IV over 30-45 minutes on day 1 (or 24-36 hours before MRI) and undergo MRI on day 2. Patients undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy with pelvic and abdominal lymph node biopsy within 2 weeks after PET/CT scan. Patients diagnosed with metastatic disease prior to lymph node biopsy proceed directly to primary treatment. Patients with cervical cancer undergo chemoradiotherapy within 4 weeks of PET/CT scan.

After completion of study therapy, patients are followed at 6 weeks, 6 months, every 3 months for 2 years, and then every 6 months for 3 years.


Recruitment information / eligibility

Status Completed
Enrollment 384
Est. completion date July 16, 2016
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of 1 of the following:

- Invasive carcinoma of the cervix meeting all of the following criteria:

- Previously untreated, primary disease

- Locoregionally advanced (stage IB2, IIA [>= 4 cm], or IIB-IVA) disease

- Any cell type allowed

- High-risk endometrial carcinoma meeting 1 of the following criteria:

- Grade 3 endometrioid or non-endometrioid endometrial carcinoma (clear cell or serous papillary) or carcinosarcoma diagnosed from an endometrial biopsy or dilation and curettage or

- Grade 1 or 2 endometrioid endometrial carcinoma with cervical stromal involvement overt on clinical examination or confirmed by endocervical curettage

- Under consideration for chemoradiotherapy (patients with cervical cancer)

- Undergone appropriate surgery for cervical or endometrial carcinoma with appropriate tissue available for histologic evaluation to confirm diagnosis and stage

- Appropriate surgical candidate to undergo extraperitoneal or laparoscopic lymph node sampling OR hysterectomy and lymph node sampling

- No surgery for patients with advanced lymphadenopathy

- No recurrent invasive carcinoma of the uterus or uterine cervix regardless of previous treatment

- No known metastases to the lungs or scalene lymph nodes

- No metastases to other organs outside of the pelvis or abdominal lymph nodes at the time of the original clinical diagnosis

- Patients with endometrial cancer with known intraperitoneal disease are eligible provided they undergo pelvic and para-aortic lymphadenectomy per protocol

- Participants must be enrolled at an American College of Radiology Imaging Network (ACRIN)-affiliated institution that is accredited by Gynecologic Oncology Group (GOG)

- GOG performance status 0-2

- Creatinine within normal institutional limits OR, in participants with creatinine levels above institutional normal, glomerular filtration rate (GFR) must be > 60 mL/min; there is no lower limit of normal for serum creatinine for this protocol

- Ferritin levels =< 600 ng/mL OR saturation of transferrin level =< 50%

- Patients with high levels of ferritin or transferrin are eligible if documented hematology rules out iron overload

- Not pregnant or nursing

- Negative pregnancy test

- No patients weighing greater than that allowable by the PET/CT scanner

- No renal abnormalities, such as a pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of the lymphadenectomy

- No history of anaphylactic or life-threatening allergic reactions to any contrast media

- No other invasive malignancies within the past 5 years with the exception of nonmelanoma skin cancer

- No contraindication to MRI (e.g., severe claustrophobia, pacemaker, aneurysm clips, defibrillators, or other institutional contraindication to MRI)

- No history of allergic reactions attributed to compounds of similar chemical or biological composition to ferumoxtran-10 (e.g., iron preparations, parenteral iron, parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide preparations)

- No immunodeficiencies that would predispose patient to specific or nonspecific mediator release

- No history of cirrhosis

- No poorly controlled, insulin-dependent diabetes (i.e., fasting blood glucose level > 200 mg/dL)

- No prior pelvic or abdominal lymphadenectomy

- No prior pelvic radiotherapy

- No prior anticancer therapy that would contraindicate study participation

- No ferumoxides within the past 2 weeks

- No investigational agents within the past 30 days

- No other concurrent investigational agents

Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Carcinoma
  • Carcinoma, Adenosquamous
  • Carcinoma, Small Cell
  • Carcinoma, Squamous Cell
  • Cervical Adenocarcinoma
  • Cervical Adenosquamous Cell Carcinoma
  • Cervical Small Cell Carcinoma
  • Cervical Squamous Cell Carcinoma
  • Endometrial Clear Cell Carcinoma
  • Endometrial Neoplasms
  • Endometrial Papillary Serous Carcinoma
  • Small Cell Lung Carcinoma
  • Stage I Endometrial Carcinoma
  • Stage IB Cervical Cancer
  • Stage II Endometrial Carcinoma
  • Stage IIA Cervical Cancer
  • Stage IIB Cervical Cancer
  • Stage III Cervical Cancer
  • Stage III Endometrial Carcinoma
  • Stage IVA Cervical Cancer
  • Uterine Cervical Neoplasms

Intervention

Radiation:
fludeoxyglucose F 18
Undergo FDG PET/CT
Procedure:
positron emission tomography
Undergo FDG PET/CT
computed tomography
Undergo FDG PET/CT
Drug:
ferumoxtran-10
Undergo femoxtran-10 MRI
Procedure:
magnetic resonance imaging
Undergo femoxtran-10 MRI
diagnostic lymphadenectomy
Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
lymph node biopsy
Undergo pelvic and abdominal lymph node biopsy

Locations

Country Name City State
Canada CHUQ - Pavilion Hotel-Dieu de Quebec Quebec City Quebec
Japan Kagoshima City Hospital Kagoshima City, Kagoshima
Japan Saitama Medical University International Medical Center Saitama
Japan Hokkaido University Hospital Sapporo Hokkaido
Korea, Republic of Keimyung University-Dongsan Medical Center Jung-Ku Daegu
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Gangnam Severance Hospital Seoul
Korea, Republic of Korea Cancer Center Hospital Seoul
Korea, Republic of Seoul National University Hospital Seoul
United States Georgia Regents University Medical Center Augusta Georgia
United States Massachusetts General Hospital Cancer Center Boston Massachusetts
United States Island Gynecologic Oncology Brightwaters New York
United States Montefiore Medical Center-Einstein Campus Bronx New York
United States Carolinas Medical Center Charlotte North Carolina
United States University of Cincinnati Cincinnati Ohio
United States Case Western Reserve University Cleveland Ohio
United States Wayne State University/Karmanos Cancer Institute Detroit Michigan
United States Brooke Army Medical Center Fort Sam Houston Texas
United States Jonsson Comprehensive Cancer Center Los Angeles California
United States University of California at Los Angeles Health System Los Angeles California
United States Vanderbilt-Ingram Cancer Center Nashville Tennessee
United States The Hospital of Central Connecticut New Britain Connecticut
United States Mount Sinai Medical Center New York New York
United States Weill Medical College of Cornell University New York New York
United States UMDNJ - New Jersey Medical School Newark New Jersey
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Providence Cancer Center -The Plaza Portland Oregon
United States Providence Portland Medical Center Portland Oregon
United States Women and Infants Hospital Providence Rhode Island
United States Mayo Clinic Rochester Minnesota
United States Sarasota Memorial Hospital Sarasota Florida
United States Olive View-University of California Los Angeles Medical Center Sylmar California

Sponsors (2)

Lead Sponsor Collaborator
National Cancer Institute (NCI) NRG Oncology

Countries where clinical trial is conducted

United States,  Canada,  Japan,  Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Diagnostic Sensitivity of PET/CT for Detection of Lymph Node Metastasis in Abdomen The sensitivity is defined as the percentage of patients who test with lymph node metastases by pre-operative PET/CT among the patients who have lymph node metastases identified by post-surgery pathology in abdomen. The reported sensitivity is reader average sensitivity by seven experienced PET-CT readers. Before surgery (FDG-PET-CT) and after surgery (pathology)
Primary The Diagnostic Specificity of PET/CT for Detection of Lymph Node Metastasis in Abdomen The specificity is defined as the percentage of patients who test without lymph node metastases by pre-operative PET/CT among the patients who do not have lymph node metastases identified by post-surgery pathology in abdomen. The reported specificity is reader average specificity by seven experienced PET-CT readers. Before surgery (FDG-PET/CT) and after surgery (pathology)
Secondary The Diagnostic Sensitivity of PET/CT for Detection of Lymph Node Metastasis in Pelvis The sensitivity is defined as the percentage of patients who test with lymph node metastases by pre-operative PET/CT among the patients who have lymph node metastases identified by post-surgery pathology in pelvis. The reported sensitivity is reader-averaged sensitivity. Before surgery (DCT) and after surgery (pathology)
Secondary The Diagnostic Specificity of PET/CT for Detection of Lymph Node Metastasis in Pelvis The specificity is defined as the percentage of patients who test without lymph node metastases in pelvis by pre-operative PET/CT among the patients who do not have lymph node metastases in pelvis identified by post-surgery pathology. The reported specificity is reader-averaged specificity. Before surgery (FDG-PET/CT) and after surgery (pathology)
Secondary The Diagnostic Sensitivity of PET/CT for Detection of Lymph Node Metastasis in Combination of Abdomen and Pelvis The sensitivity is defined as the percentage of patients who test with lymph node metastases by pre-operative PET/CT among the patients who have lymph node metastases identified by post-surgery pathology in combination of abdomen and pelvis. The reported sensitivity is reader-average sensitivity. Before surgery (FDG-PET/CT) and after surgery (pathology)
Secondary The Diagnostic Specificity of PET/CT for Detection of Lymph Node Metastasis in Combination of Abdomen and Pelvis The specificity is defined as the percentage of patients who test without lymph node metastases by pre-operative PET/CT among the patients who do not have lymph node metastases identified by post-surgery pathology in combination of abdomen and pelvis. The reported specificity is reader-averaged specificity. Before surgery (FDG-PET/CT) and after surgery (pathology)
Secondary Sensitivity for Detection of Lymph Node Metastasis in Abdomen by CT Alone The sensitivity is defined as the percentage of patients who test with lymph node metastases by pre-operative CT alone among the patients who have lymph node metastases identified by post-surgery pathology in abdomen. The reported estimate of sensitivity is reader-average sensitivity across all 7 experienced PET-CT readers. Before surgery (FDG-PET/CT) and after surgery (pathology)
Secondary Sensitivity for Detection of Lymph Node Metastasis in Pelvis by CT Alone The sensitivity is defined as the percentage of patients who test with lymph node metastases by pre-operative either CT alone among the patients who have lymph node metastases identified by post-surgery pathology in pelvis. The reported estimate of sensitivity is reader-average sensitivity across all 7 experienced PET-CT readers. Before surgery (FDG-PET/CT) and after surgery (pathology)
Secondary Sensitivity Between for Detection of Lymph Node Metastasis in Combination of Abdomen and Pelvis by CT Alone The sensitivity is defined as the percentage of patients who test with lymph node metastases by pre-operative by CT alone among the patients who have lymph node metastases identified by post-surgery pathology in pelvis. The reported estimate of sensitivity is reader-average sensitivity across all 7 experienced PET-CT readers. Before surgery (FDG-PET/CT) and after surgery (pathology)
Secondary Specificity for Detection of Lymph Node Metastasis in Abdomen by CT Alone The specificity is defined as the percentage of patients who test without lymph node metastases by pre-operative CT alone among the patients who do not have lymph node metastases identified by post-surgery pathology in pelvis. The reported estimate of specificity is reader-average specificity across all 7 experienced PET-CT readers. Before surgery (FDG-PET/CT) and after surgery (pathology)
Secondary Specificity Between for Detection of Lymph Node Metastasis in Pelvis by CT Alone The specificity is defined as the percentage of patients who test without lymph node metastases by pre-operative byCT alone among the patients who do not have lymph node metastases identified by post-surgery pathology in pelvis. The reported estimate of specificity is reader-average specificity across all 7 experienced PET-CT readers. Before surgery (FDG-PET/CT) and after surgery (pathology)
Secondary Specificity for Detection of Lymph Node Metastasis in Combination of Abdomen and Pelvis by CT Alone The specificity is defined as the percentage of patients who test without lymph node metastases by pre-operative CT alone among the patients who do not have lymph node metastases identified by post-surgery pathology in pelvis. The reported estimate of specificity is reader-average specificity across all 7 experienced PET-CT readers. Before surgery (FDG-PET/CT) and after surgery (pathology)
Secondary Percentage of Participants in Whom PET/CT Detects Biopsy-proven Disease Outside the Abdominal Lymph Nodes Before surgery (FDG-PET/CT) and after surgery (pathology)
Secondary Percentage of Participants in Whom PET/CT Detects Biopsy-proven Disease Outside the Pelvic Lymph Node Before surgery (FDG-PET/CT) and after surgery (pathology)
Secondary Cervical Cancer Patients With Adverse Events (Grade 3 or Higher) at Least Possibly Attributed to Extra-peritoneal or Laparoscopic Abdominal and Pelvic Lymphadenectomy Number of participants with cervical cancer and a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v3.0. During surgery and up to 30 days after surgery.
Secondary Cause of Delay in the Initiation of Chemo-radiation Therapy More Than 4 Weeks After PET/CT for Cervical Cancer Patients Number of cervical cancer patients with reasons of delay in the initiation of chemo-radiation therapy Within 4 weeks from PET/CT
Secondary Cause of Interruption in Radiation Therapy in Cervical Cancer Patients Number of cervical cancer patients with reasons of interruption in radiation therapy Within 6 weeks after surgery
See also
  Status Clinical Trial Phase
Completed NCT02562729 - Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Phase 2
Completed NCT00054444 - Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer Phase 1
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Active, not recruiting NCT02140021 - Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer N/A
Completed NCT00068549 - Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer Phase 1
Completed NCT01711515 - Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer Phase 1
Terminated NCT00924066 - Ixabepilone to Treat Cervical Cancer Phase 2
Completed NCT00559377 - FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Phase 2
Completed NCT00309959 - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Active, not recruiting NCT05613283 - Primary Cervical Cancer Screening by Self-sampling HPV Test
Recruiting NCT03742869 - HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma
Withdrawn NCT03834571 - Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women Phase 2
Completed NCT01266460 - Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Completed NCT00064077 - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Phase 3
Active, not recruiting NCT02257528 - Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Phase 2
Active, not recruiting NCT02466971 - Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Phase 3
Completed NCT02164461 - Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Phase 1
Completed NCT01281852 - Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Phase 1
Active, not recruiting NCT04622670 - Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer N/A
Completed NCT02921269 - Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Phase 2